To match an exact phrase, use quotation marks around the search term. eg. "Parliamentary Estate". Use "OR" or "AND" as link words to form more complex queries.


View sample alert

Keep yourself up-to-date with the latest developments by exploring our subscription options to receive notifications direct to your inbox

Written Question
Parkinson's Disease: Health Services
Wednesday 27th March 2024

Asked by: Rachael Maskell (Labour (Co-op) - York Central)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps she is taking to help ensure patients diagnosed with Parkinson's disease receive an appointment with a specialist within six weeks.

Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)

The National Institute for Health and Care Excellence’s (NICE) guidance, Parkinson’s disease: Diagnosis and management in primary and secondary care, updated in 2017, sets out best practice for clinicians in the identification and treatment of Parkinson’s disease in line with the latest available evidence. The guidance states that if Parkinson’s disease is suspected, people should be referred quickly and without treatment to a specialist with expertise in the differential diagnosis of this condition.

We expect integrated care boards (ICBs) and National Health Service trusts to have due regard to relevant NICE guidelines. It is the responsibility of ICBs to make available the appropriate provision to meet the health and care needs of their local population, in line with these NICE guidelines.

More generally, cutting waiting lists is one of the Prime Minister’s top priorities. We are making good progress on tackling the longest waits, to ensure patients get the care they need when they need it. Ambitions to eliminate long waits were set out in the elective recovery plan, with the overall aim of eliminating waits of over a year for elective care, by March 2025.

To facilitate this across elective services, we are increasing activity, with plans to spend more than £8 billion from 2022/23 to 2024/25. This includes expanding capacity through the creation of a new network of community diagnostic centres, and maximising all available independent sector capacity.


Non-Departmental Publication (Transparency)
Medicines and Healthcare products Regulatory Agency

Mar. 14 2024

Source Page: Freedom of Information responses from the MHRA - week commencing 4 December 2023
Document: FOI 23/857 - attachment 2 (PDF)

Found: Burning sensation 4 0 Formication 1 0 Hypoaesthesia 17 0 Paraesthesia 27 0 Parkinson's


Non-Departmental Publication (Transparency)
Medicines and Healthcare products Regulatory Agency

Mar. 14 2024

Source Page: Freedom of Information responses from the MHRA - week commencing 4 December 2023
Document: FOI 23/774 - attachment 2 (PDF)

Found: coronary artery bypass (1), acute my ocardial infarct ion (1), alcoholic (1), deficiency anaem ia (1), Parkinson's


Written Question
Chronic Illnesses: Government Assistance
Wednesday 6th March 2024

Asked by: Paul Girvan (Democratic Unionist Party - South Antrim)

Question to the Department for Work and Pensions:

To ask the Secretary of State for Work and Pensions, what steps he is taking to support people with (a) Parkinson's and (b) other long-term conditions with their basic financial outgoings.

Answered by Mims Davies - Parliamentary Under-Secretary (Department for Work and Pensions)

People on low, or no income or earnings who have a health condition or disability which restricts the amount of work they can do, can claim Universal Credit (UC). They must provide medical evidence to support their claim - most commonly a Statement of Fitness for Work, usually referred to as a fit note. Claimants whose health condition or disability continues for four weeks or more are referred for a work capability assessment (WCA). The WCA determines how an individual’s health condition or disability affects their ability to work. A key principle is that the WCA considers the impact a person’s disability or health condition has on them, not the condition itself.

Where it has been decided that claimants have limited capability for work (LCW) or limited capability for work and work-related activity (LCWRA), they will be entitled to a work allowance, and in couple claims where one is working, access to help with childcare costs.  Where it has been decided that claimants have LCWRA, they may be entitled to the award of an additional amount of benefit – the LCWRA addition – which is £390.06 per month (2023-24 rates).

Where it has been decided that claimants have LCW, they are not reasonably expected to look for work at present but are expected to prepare for work in the future. Where it has been decided that claimants have LCWRA, they are not expected to look for work or required to undertake any work-related activity. Where it has been decided that claimants are fit for work, they are expected to undertake work-related activity and to look for work.

People whose capability for work is impacted because they are disabled or have a health condition, including people who have Parkinson’s and other long term health conditions, may also be eligible for New Style Employment and Support Allowance (NS ESA) subject to satisfying both the basic and National Insurance contribution conditions. NS ESA is an earnings replacement benefit for working age people who are unable to work due to a health condition or disability. In addition to the support provided for basic financial outgoings by UC people with a long-term health condition or disability may be entitled to support with disability-related extra costs through benefits such as Personal Independence Payment.


Written Question
Cost of Living: Parkinson's Disease
Tuesday 5th March 2024

Asked by: Taiwo Owatemi (Labour - Coventry North West)

Question to the HM Treasury:

To ask the Chancellor of the Exchequer, what assessment he has made of the implications for his policies of the recommendations in the report entitled Still nowhere near enough, published by Parkinson’s UK on 26 February 2024.

Answered by Laura Trott - Chief Secretary to the Treasury

HM Treasury ministers have regular discussions with Department for Health and Social Care ministers on a range of issues, including meetings between the Chancellor and the Secretary of State


The Government delivers a wide range of support to help those with disabilities and long-term health conditions, such as Parkinson’s. If individuals incur extra costs whilst performing tasks associated with daily living, then they may qualify for disability benefits such as Personal Independence Payment (PIP) and Attendance Allowance (AA). This extra support can be worth over £8,900 per year and is due to increase from April by 6.7%. Depending on their needs, additional support for those with Parkinson’s may be available via local authorities who deliver adult social care services.


Written Question
Chronic Illnesses: Government Assistance
Tuesday 5th March 2024

Asked by: Taiwo Owatemi (Labour - Coventry North West)

Question to the HM Treasury:

To ask the Chancellor of the Exchequer, what steps he is taking to support people with (a) Parkinson's and (b) other long-term conditions to cover everyday expenses.

Answered by Laura Trott - Chief Secretary to the Treasury

HM Treasury ministers have regular discussions with Department for Health and Social Care ministers on a range of issues, including meetings between the Chancellor and the Secretary of State


The Government delivers a wide range of support to help those with disabilities and long-term health conditions, such as Parkinson’s. If individuals incur extra costs whilst performing tasks associated with daily living, then they may qualify for disability benefits such as Personal Independence Payment (PIP) and Attendance Allowance (AA). This extra support can be worth over £8,900 per year and is due to increase from April by 6.7%. Depending on their needs, additional support for those with Parkinson’s may be available via local authorities who deliver adult social care services.


Written Question
Chronic Illnesses: Government Assistance
Tuesday 5th March 2024

Asked by: John Hayes (Conservative - South Holland and The Deepings)

Question to the HM Treasury:

To ask the Chancellor of the Exchequer, what steps he is taking to support people with (a) Parkinson's and (b) other long-term conditions to cover everyday expenses.

Answered by Laura Trott - Chief Secretary to the Treasury

HM Treasury ministers have regular discussions with Department for Health and Social Care ministers on a range of issues, including meetings between the Chancellor and the Secretary of State


The Government delivers a wide range of support to help those with disabilities and long-term health conditions, such as Parkinson’s. If individuals incur extra costs whilst performing tasks associated with daily living, then they may qualify for disability benefits such as Personal Independence Payment (PIP) and Attendance Allowance (AA). This extra support can be worth over £8,900 per year and is due to increase from April by 6.7%. Depending on their needs, additional support for those with Parkinson’s may be available via local authorities who deliver adult social care services.


Written Question
Parkinson's Disease: Drugs
Tuesday 27th February 2024

Asked by: Tonia Antoniazzi (Labour - Gower)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what discussions she has had with the Medicines and Healthcare products Regulatory Agency on the average licensing approval decision timelines for (a) generic and (b) biosimilar medicines to treat Parkinson's disease.

Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)

The Medicines and Healthcare products Regulatory Agency (MHRA) is taking urgent action to deliver improvements to decision timescales in established medicines, including those indicated to treat Parkinson’s disease. Last week we approved additional licences for this critical area. Whilst no specific discussions have taken place between the MHRA and my Rt hon. Friend, the Secretary of State for Health and Social Care on this matter, we are taking significant steps to assess applications for medicine approval within statutory timeframes and will always prioritise applications according to public health need.

We are working to reduce timelines by bringing in additional resources and developing processes that will result in significantly improved response times, while protecting patient safety. The measures we are putting in place are already resulting in significant improvements, and we will continue to publish monthly updates providing applicants with transparent information on expected timescales. As an effective regulator, we are committed to the highest of standards of performance and delivering the right outcomes for patients and public health.


Written Question
Parkinson's Disease: Drugs
Tuesday 27th February 2024

Asked by: Tonia Antoniazzi (Labour - Gower)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether she is taking steps with the Medicines and Healthcare products Regulatory Agency to reduce the time taken to license (a) generic and (b) biosimilar medicines to treat Parkinson's disease.

Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)

The Medicines and Healthcare products Regulatory Agency (MHRA) is taking urgent action to deliver improvements to decision timescales in established medicines, including those indicated to treat Parkinson’s disease. Last week we approved additional licences for this critical area. Whilst no specific discussions have taken place between the MHRA and my Rt hon. Friend, the Secretary of State for Health and Social Care on this matter, we are taking significant steps to assess applications for medicine approval within statutory timeframes and will always prioritise applications according to public health need.

We are working to reduce timelines by bringing in additional resources and developing processes that will result in significantly improved response times, while protecting patient safety. The measures we are putting in place are already resulting in significant improvements, and we will continue to publish monthly updates providing applicants with transparent information on expected timescales. As an effective regulator, we are committed to the highest of standards of performance and delivering the right outcomes for patients and public health.


Scottish Parliament Select Committee
A report on Stage 1 scrutiny of the general principles of the National Care Service (Scotland) Bill by the Health, Social Care and Sport Committee of the Scottish Parliament.
Stage 1 report on the National Care Service (Scotland) Bill

Report Feb. 22 2024

Committee: Health, Social Care and Sport Committee

Found: worst it was feared that this approach can lead to cuts to social care packages or reduced support.14 Parkinson's